The researchers said that they have demonstrated an approach that skirts a bottleneck and enables building pathology support systems from large datasets.
Israel-based software company Medial EarlySign will work with Geisinger's innovation center to develop technologies to predict lower GI and other "high-burden" diseases.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
The companies anticipate providing services that combine Flagship’s biomarker development and Indivumed’s multiplex IHC assay development capabilities.
Singapore-based Lucence Diagnostics will team with Stanford to analyze sequencing and imaging of liver cancer patients to predict therapeutic effectiveness.
